meta
|
evidence
oncology
Living systematic review and meta-analysis
endometrial cancer - (neo)adjuvant (NA)
1
esophageal cancer (EC)
immune chekpoint inhibitors
anti-PD-(L)1
camrelizumab based treatment
camrelizumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
vs non active control
vs no additional treatment
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab plus SoC
title
placebo plus SoC
title
KEYNOTE-590, 0 NCT03189719 mEC - 1st line (L1) 373/376
Pathology:
mEC - 1st line (L1);
mEC - 1st line (L1)
KEYNOTE-590, 0
pembrolizumab plus SoC
1
T1
placebo plus SoC
0
T0